Author

G. Ngo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. C. Chambers· 1 shared A. C. Williams· 1 shared C. Parker· 1 shared D. Abba Moussa· 1 shared D. Flanagan· 1 shared D. M. Baird· 1 shared D. MURIAUX· 1 shared E. Reynaud· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. C. Chambers

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comprehensive Analysis of Neutrophil Immunomodulatory Properties and FcR Dynamics in Health and HIV-1 Infection and Therapy

S. Marsile-Medun, M. Souchard, D. Abba Moussa, V. Lorin, H. Mouquet, E. Reynaud, R. Dibsy, E. TUAILLON, D. MURIAUX, G. Ngo, M. Pugniere, M. Naranjo-Gomez, M. Pelegrin

The paper examines neutrophil immunomodulatory properties and FcR dynamics in HIV-1 infection and therapy, finding altered cytokine production and FcR expression in PLWH.

bioRxiv · Feb 13, 2024Immunology

Loss of BCL-3 sensitises colorectal cancer cells to DNA damage, revealing a role for BCL-3 in double strand break repair by homologous recombination

C. Parker, A. C. Chambers, D. Flanagan, T. J. Collard, G. Ngo, D. M. Baird, P. Timms, R. G. Morgan, O. J. Sansom, A. C. Williams

This study shows that loss of BCL-3 increases DNA damage and reduces homologous recombination in colorectal cancer cells, suggesting BCL-3 as a potential target to enhance DNA damage therapy response.

bioRxiv · Aug 3, 2021 · PreprintCancer Biology